BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine

Ann Intern Med. 2021 Nov;174(11):JC123. doi: 10.7326/ACPJ202111160-123. Epub 2021 Nov 2.

Abstract

Borobia AM, Carcas AJ, Perez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121-30. 34181880.

Publication types

  • Comment

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Immunity
  • Immunogenicity, Vaccine
  • SARS-CoV-2
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines
  • BNT162 Vaccine